Balloon Angioplasty as the First-Choice Treatment for Intracranial Atherosclerosis-Related Emergent Large Vessel Occlusion Involving the Microcatheter “First-Pass Effect”

INTRODUCTION

Mechanical thrombectomy (MT) has been the gold-standard of reperfusion therapy for patients with emergent large vessel occlusion (ELVO); however, these studies’ participants predominantly originated from Western populations, and the primary etiology of vascular occlusion was embolism ^1-5. When treating intracranial atherosclerosis-related emergent large vessel occlusion (ICAS-ELVO), MT results in a lower recanalization rate, longer procedure times, and poorer outcomes than when treating embolism-induced vessel occlusion, and a significant number of patients require rescue therapy ^6-9. Patients with ICAS-ELVO encounter unique technical challenges during endovascular recanalization therapy.

ICAS-ELVO is related to in-situ atherothrombotic occlusion and usually has a smaller clot burden ¹⁰, for which MT is often inefficient. Moreover, additional and repeated MT tends to damage the vascular endothelium and increases the risk of reocclusion. Balloon angioplasty has proven safe in ICAS-ELVO rescue therapy following MT, and we speculate that it may be a better first-choice treatment than MT for ICAS-ELVO in patients with a small clot burden.

Though certain studies have demonstrated the feasibility of direct angioplasty for patients with ICAS-ELVO ^11-14, these studies did not define the clot burden of the included patients. The microcatheter “first-pass effect” is considered a valid predictor of ICAS-ELVO¹⁵, and it often suggests an occluded vessel with a small clot burden. Thus, we conducted this retrospective study to determine whether balloon angioplasty could be the first-choice treatment for ICAS-ELVO in patients with small clot burden, which was defined through the microcatheter “first-pass effect” that presented during endovascular treatment (EVT).

METHODS

Patients

We reviewed the information of the consecutively collected ELVO patients who underwent EVT between October 2018 and December 2021 in Shenzhen Hospital of Southern Medical University. We enrolled patients who:(i) were aged >18 years, (ii) presented with isolated intracranial internal carotid artery (ICA), M1 of middle cerebral artery, intracranial vertebral artery or basilar artery occlusion, and (iii) the microcatheter “first-pass effect” was evaluated before EVT. Patients were divided into two first-choice treatment-based groups: preferred balloon angioplasty (PBA) and preferred mechanical thrombectomy (PMT). A flowchart of the selection process is shown in Figure 1.

• Download figure
• Open in new tab

Figure 1.

Flow chart of patient screening in this study

The etiologies of vessel occlusion and the microcatheter “first-pass effect” were assessed by two neurointerventionalists using clinical and imaging data. The definition of the microcatheter “first-pass effect” has been described in a previous study ¹⁵, and microcatheters used in this study mainly were the XT-27^® (Stryker Inc, Kalamazoo, MI, USA) and Rebar-27^® (Medtronic Inc, Minneapolis, MN, USA). Illustrative cases of the microcatheter “first-pass effect” are shown in Figure 2. The basis for determining ICAS-ELVO included: (i) clear evidence of ICAS as the culprit occluded vessel prior to this ischemic event; (ii) procedural evidence of ICAS after the first pass of the microcatheter or balloon dilation/stent deployment; and (iii) significant fixed focal stenosis (stenotic degree ≥ 50%) at the occlusion site. To reduce bias, both neurointerventionists were tested in 10 selected cases of ELVO whose etiology was identified as ICAS, and the diagnostic accuracy was 100%. This study was approved by our local medical ethics committee.

• Download figure
• Open in new tab

Figure 2.

Illustrative cases of the microcatheter “first-pass effect.” (1): A 51-year-old male patient with hypertension and diabetes for 5 years presented with an acute onset of left body weakness (iNIHSS score: 9) for 11 h. Angiography revealed occlusion at the M1 segment of the right MCA and “taper sign” (A); Angiography exhibited adequate collateral, and retro-flow reconstituted the distal portion of M1 (B); An XT-27 microcatheter and a microwire were navigated through the occlusion area to the distal patent artery, and the microcatheter was subsequently withdrawn to the occlusion’s proximal side. Angiography demonstrated blood flow through the vessel at the occlusion site, which was defined as the microcatheter “first-pass effect” (C); Direct balloon angioplasty (gateway 2.0 × 9.0 mm) achieved an mTICI score of 3 (D). (2): A 65-year-old male patient with hypertension for 11 years presented with unconsciousness (iNIHSS score: 15) for 4 h. Angiography demonstrated that the V5 segment of the right dominant vertebral artery was occluded (E); Angiography revealed the microcatheter “first-pass effect” (F); Direct balloon angioplasty (Sino 2.25 × 15.0 mm) achieved an mTICI score of 2b with focal dissection (G); An enterprise stent (4 × 39 mm) was placed at the stenotic site, and angiography revealed an mTICI score of 3 (H).

RESULTS

DISCUSSION

For patients with ICAS-ELVO involving the microcatheter “first-pass effect” during EVT, two preferred treatments—MT and balloon angioplasty—were used for recanalization in this study. Our results indicate that the two treatments were comparable in terms of safety. However, they also show that balloon angioplasty, as the first-choice treatment, potentially increases the FPR and complete reperfusion rates, shortens the puncture-to-recanalization time, reduces the rescue therapy rate, and improves patients’ 90-day outcomes.

MT is often accompanied by a lower recanalization rate, longer operation time, and a higher risk of vascular reocclusion in patients with ICAS-ELVO, a phenomenon that has always challenged neurointerventionalists. Owing to the special pathophysiological characteristics of ICAS-ELVO, researchers are attempting to develop a targeted EVT strategy based on etiological diagnosis.

Certain studies have reported the advantages of direct angioplasty as a primary treatment for ICAS-ELVO, including shortening the procedure time and reducing the number of procedure device attempts, with similar safety to that of MT ^13,14. However, these studies did not define the clot burden of the included patients, thus potentially affecting the persuasiveness of the results. ICAS-ELVO is related to in situ thrombotic occlusion, which results from unstable plaque ruptures and typically has a smaller clot burden; however, it is not absolute. Studies have demonstrated that clot burdens are associated with patient prognosis after EVT ¹⁹, and balloon angioplasty, as the first-choice treatment for ICAS-ELVO, is often ineffective in cases of large clot burdens. Thus, considering the clot burden as one of the bases for developing an EVT strategy for patients with ICAS-ELVO is recommended. Although the clot burden score ^20,21 has been used to evaluate clot burdens, its extensive and accurate evaluation in clinical practice remains challenging. The microcatheter “first-pass effect” is a valuable predictor of ICAS-ELVO based on the condition’s small clot size and relative ease of disintegration; when the microcatheter passes through the occlusive site, it pushes part of the fresh thrombus to the blood vessel’s distal end. Thus, the microcatheter “first-pass effect” may also be an effective indicator of a small clot burden and an important variable for planning the ICAS-ELVO EVT strategy. Rapid and complete reperfusion after thrombectomy is a predictor of favorable outcomes in ELVO stroke ^16,22. However, in patients with ICAS-ELVO, vessels tend to reocclude after recanalization due to post-MT endothelial injury, and repeated MT and/or angioplasty must be performed, thus substantially delaying reperfusion. Moreover, despite achieving successful vessel recanalization after MT, a considerable number of patients fail to achieve complete reperfusion because of residual stenosis. In this study, we compared the rates of FPR, complete reperfusion (eTIC≥2c), and 90-day excellent functional outcomes (mRS≤1) between PBA and PMT patients with ICAS-ELVO involving the microcatheter “first-pass effect” during EVT. The results revealed that balloon angioplasty, as the first-choice treatment, potentially increases the FPR and complete reperfusion rates and shortens the puncture-to-recanalization time; moreover, the puncture-to-recanalization time and FPR rate were significantly correlated with 90-day excellent functional outcomes. Our study implies that, for patients with ICAS-ELVO, balloon angioplasty that entails selecting an appropriate balloon size and dilatation pressure for angioplasty may be less invasive to the vascular endothelium than MT, which is beneficial for maintaining vascular stability after the first recanalization.

EVT is recognized as an effective method for ELVO and has been increasingly promoted worldwide. However, cost is often an important consideration for families and patients when deciding on EVT, especially for self-funded patients with ICAS-ELVO. Given the complexity of MT for ICAS-ELVO, neurointerventionalists often tend to estimate relatively high surgical costs, thus further increasing the concern of the patient’s family. Previous studies have observed that direct balloon angioplasty can reduce the number of procedure device attempts in patients with ICAS-ELVO; however, its ability to alleviate surgical costs has not been discussed. Our results indicate that balloon angioplasty, as the first-choice treatment, potentially reduces the use of remedial measures, thus relieving the economic burden on patients with ICAS-ELVO. Considering that approximately one-third of ischemic strokes in Asia are caused by ICAS, ensuring the effectiveness of EVT while reducing the cost as much as possible will benefit a greater number of patients.

Emergency balloon angioplasty’s major cause for concern is its increased risk of reocclusion without adequate antiplatelet therapy or cerebral hemorrhage when antiplatelet therapy is administered within 24 h of intravenous thrombolysis. Tirofiban is a short-acting intravenous antiplatelet drug widely used in percutaneous coronary intervention, and studies have proven that the combined use of tirofiban during or before EVT is feasible in patients with ICAS-ELVO ^11,23-25. Furthermore, tirofiban may be an alternative therapy for patients with post-MT ICAS-ELVO ²⁶. In this study, we found that balloon angioplasty, as the first-choice treatment, neither increased tirofiban use nor amplified the risk of symptomatic intracranial hemorrhage. In contrast, tirofiban use was more aggressively required in the PMT group owing to endothelial injury caused by additional and repeat MT. Another cause for concern in balloon angioplasty is the “snowplowing” effect: branch occlusion following angioplasty may cause secondary ischemia in the injury site. However, because the territory supplied by the neighboring side branches is often already infarcted following the complete occlusion of the trunk vessel, the risk of secondary ischemic injury due to “snowplowing” is not as high as anticipated ⁸.

Planning a targeted EVT strategy based on etiological diagnosis is an attractive option; however, predicting the etiology of vascular occlusion promptly and accurately before EVT remains difficult. Currently, no widely accepted diagnostic criteria for distinguishing atherothrombotic ELVO from others and potential preprocedural methods for identifying signs of atherosclerosis are available. For example, patients repeatedly suffering from transient ischemic attack-related symptoms on the ipsilateral side before acute ischemic stroke, combined with risk factors associated with atherosclerosis, have exhibited lower NIHSS scores and favorable collateral circulation upon admission, which leads to the suspicion of ICAS-ELVO ⁹. Imaging predictors, such as a core infarction located in the watershed area, severe calcification at the site of occlusion, severe and/or multifocal narrowing on angiography, “tapered” occlusion ²⁷, “truncal-type” occlusion ²⁸, and the microcatheter “first-pass effect,” ¹⁵ all support ICAS as the most likely etiology. In the future, more diagnostic methods that enable the rapid and accurate diagnosis of vascular occlusion’s etiology and provide a basis for treatment decisions are warranted.

Limitations

There were several limitations in this study. First, our findings should be cautiously interpreted, as the study is characterized by a small sample size, single center, and retrospective nature; therefore, further prospective, multicenter, large sample-sized studies are required. Second, although a small clot burden is the prerequisite for the existence of microcatheter “first-pass effect,” its specificity and sensitivity to predict small clot burden need to be further tested in more studies.

CONCLUSION

Our study reveals that balloon angioplasty, as the first-choice treatment, is potentially beneficial in improving the rate of 90-day excellent functional outcomes, shortening the procedure time, and reducing surgical costs for patients with ICAS-ELVO involving the microcatheter “first-pass effect” during EVT. In the future, the rapid and accurate diagnosis of the etiology and clot burden of ELVO and development of an individualized EVT strategy based on etiology and clot burden will be the focus of our subsequent research.

Conflict of Interest

None.

Disclosure of Funding

None.

Author Contributions

L.Z. and X.H. analyzed and interpreted the data and drafted the manuscript. Y.L. conceived and designed the research. M.P. and K.L. evaluated the image. L.L. and L.H. made critical revisions of the manuscript. All authors read and approved the final manuscript.

Ethical Statement

The studies involving human participants were reviewed and approved by the Clinical Research Ethics Committee of Shenzhen Hospital of Southern Medical University. The patients/participants provided written informed consent to participate in this study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

FIGURE LEGENDS

Supplementary Figure 1. Comparison of modified Rankin Scale (mRS) scores at 90 days between the two groups